Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The Locations section has been expanded to include many new sites across the US, Australia, Canada, and numerous other countries, replacing the previous shorter list. This broadens geographic availability of trial sites.
    Difference
    4%
    Check dated 2025-12-19T12:55:43.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page footer revision tag has been updated from Revision: v3.3.1 to Revision: v3.3.2.
    Difference
    0.0%
    Check dated 2025-11-28T04:13:27.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Publications section now clarifies that some items are voluntarily provided and that PubMed-sourced publications are auto-filled; the page also shows revision v3.3.1.
    Difference
    0.5%
    Check dated 2025-11-21T00:40:28.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The Taiwan location entry was updated to standardize the city name to 'Tainan, Taiwan, 70457'. The old entry 'Tainan City, Taiwan, 70457' was removed and the new listing added.
    Difference
    0.2%
    Check dated 2025-11-13T21:37:10.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    Added a study site: Cali, Valle del Cauca Department, Colombia, 760023, and removed Santiago de Cali, Valle del Cauca Department, Colombia, 760023 from the locations list.
    Difference
    0.2%
    Check dated 2025-10-30T12:00:20.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    Update to a newer revision identifier (v3.2.0) replaces the older v3.0.2.
    Difference
    0.0%
    Check dated 2025-10-01T05:55:53.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.